Friday, 29 March 2024
Global Blood Therapeutics Inc.
03:03 | 15/3/18
Stock Watch
After a recent check, Global Blood Therapeutics Inc., (NASDAQ: GBT)'s last month price volatility comes out to be 5.43% which for the week stands at 6.16%.
more»
10:30 | 14/3/18
Equities.com
Global Blood Therapeutics Inc. (GBT) traded on unusually high volume on Mar. 13, as the stock lost 0.56% to close at $53.75.
more»
02:41 | 14/3/18
Alpha Beta Stock
The stock market finished mostly lower Monday, weighed down by the industrials sector, while the Nasdaq closed at a record, in part because of optimism over Friday's jobs data, which showed solid economic growth without triggering wage pressure.
more»
10:22 | 13/3/18
Equities.com
Global Blood Therapeutics Inc. (GBT) had a rough trading day for Monday March 12 as shares tumbled 5.42%, or a loss of $-3.1 per share, to close at $54.05.
more»
Risk Alert: Before we dive into any analysis we simply note that Global Blood Therapeutics Inc (NASDAQ:GBT) risk is elevated.
more»
01:56 | 13/3/18
Market Exclusive
The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the ...
more»
11:30 | 9/3/18
Equities.com
Global Blood Therapeutics Inc. (GBT) had a rough trading day for Thursday March 08 as shares tumbled 5.4%, or a loss of $-3.25 per share, to close at $56.90.
more»
10:00 | 9/3/18
GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous ...
more»
01:56 | 7/3/18
GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the “Company”) (Nasdaq:GBT) today announced the appointment of David L. Johnson as chief commercial officer, effective March 12, 2018.
more»
21:03 | 5/3/18
StockNewsTimes
The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |